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Abstract
Background: Vaccine efficacy depends significantly on the use of appropriate adjuvant(s) in the
formulation. Phytol, a dietary diterpene alcohol, is similar in structure to naturally occurring
isoprenoid adjuvants; but little is known of its adjuvanticity. In this report, we describe the relative
safety and efficacy of phytol and its hydrogenated derivative PHIS-01 compared to commercial
adjuvants.
Methods:  We tested adjuvant properties using a formulation consisting of either a hapten,
phthalate-conjugated to a protein, keyhole limpet hemocyanin (KLH), or ovalbumin (OVA)
emulsified with the test adjuvants in mice without any surfactant. Humoral immunity was assessed
in terms of titer, specificity, and isotypic profiles. The effect on cell-mediated immunity was studied
by assaying the induction of either OVA- or B-lymphoma-specific cytotoxic T-lymphocyte (CTL)
activity.
Results and Discussion: The phytol compounds, particularly PHIS-01, elicit increased titers of all
major IgG subclasses, especially IgG2a. Unlike commercial adjuvants, both phytol compounds are
capable of inducing specific cytotoxic effector T cell responses specific to both OVA and B-
lymphoma tested. Phytols as adjuvants are also distinctive in that they provoke no adverse anti-
DNA autoimmune response. Intraperitoneally administered phytol is comparable to complete
Freund's adjuvant in toxicity in doses over 40 ug/mouse, but PHIS-01 has no such toxicity.
Conclusion: These results and our ongoing studies on antibacterial immunity show that phytol
and PHIS-01 are novel and effective adjuvants with little toxicity.
Background
Designing effective vaccines depends not only on the
nature of the antigens (Ag), but also on the inclusion of
appropriate adjuvants to ensure optimum induction of
protective immunity. The immunogenicity of a protein is
inherently linked to its physico-chemical properties, but
adjuvants can significantly influence the amplitude of the
response. Traditionally, vaccines have consisted of attenu-
Published: 30 October 2006
Journal of Immune Based Therapies and Vaccines 2006, 4:6 doi:10.1186/1476-8518-4-6
Received: 20 September 2006
Accepted: 30 October 2006
This article is available from: http://www.jibtherapies.com/content/4/1/6
© 2006 Lim et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Immune Based Therapies and Vaccines 2006, 4:6 http://www.jibtherapies.com/content/4/1/6
Page 2 of 11
(page number not for citation purposes)
ated/killed microorganisms, or isolated components. In
recent years, vaccine formulations have included specific
and safer recombinant proteins, synthetic peptides, and
even vectored DNA [1,2]. In general, these vaccines are
not as effective as those based on whole organisms, but
the efficacy is often enhanced when used in conjunction
with non-specific immunoadjuvants [3-5].
Adjuvant activity has been demonstrated in numerous
natural products through serendipity and by trial and
error [6,7]. However, in selecting adjuvants, their immu-
nological properties are as important as their benefit-to-
toxicity ratio. Adjuvants are often foreign to the body and
thus capable of producing adverse reactions. These
adverse effects can be a direct consequence of toxic or
non-metabolizable components in their formulation or
can result from the inclusion of agents that overstimulate
the immune or inflammatory systems [8]. For example,
CFA, which is used widely in experimental studies, pro-
duces excellent humoral and cell-mediated immunity, but
is unsuitable for human and veterinary purposes because
of toxicity. Hence, there is a need for identification of
adjuvants that are both safe and efficacious.
The search for potentially useful adjuvants has often led to
the use of isoprenoid compounds extracted from plant
sources [9-12]. Because some of these compounds can be
toxic, we considered developing isoprenoid adjuvants
from substances that are common in the human diet. Epi-
demiological studies suggest that green vegetables in diets
improve resistance to infection, and thus enhance immu-
nity [13-15]. They may also help prevent some cancers by
augmenting immunological responses against emerging
neoplasms in the early stages of carcinogenesis [16-18].
Chlorophylls in green vegetables constitute an important
source of an isoprenoid component, phytol (3, 7, 11, 15-
tetramethyl-2-hexadecen-1-ol, C20H40O), a branched
aliphatic alcohol, also present as the fatty acid side chain
in tocopherols. Because phytols are hydrophobic, they are
capable of interacting with the cell membrane. A number
of recent studies have described various cellular and bio-
logical effects of phytol (19–21). However, there is as yet
no definitive report on the adjuvanticity of phytol or any
synthetic derivatives such as hydrogenated phytol or
phytanol, named PHIS-01 (Patent pending) which has
been studied in our laboratory.
In this report, we compared the adjuvant potential of both
phytol and PHIS-01 to that of some commonly used adju-
vants (Complete and incomplete Freund's adjuvants,
TiterMax, Ribi's adjuvant system, and Alhydrogel). Since
phytol and PHIS-01 are structurally similar to the mineral
oil constituents in IFA and CFA, we included pristane for
comparison as the protype mineral oil in this study. Most
of these common adjuvants are not equally capable of
enhancing either humoral and/or cellular responses
against an immunogen. Moreover, their inclusion in vac-
cine formulations can engender adverse side effects,
including the induction of anti-DNA antibody responses,
the hallmark of lupus-like autoimmune disorders [22,23].
We demonstrate here that phytol, and to a greater extent
phytol-derived PHIS-01, exhibit excellent adjuvanticity at
low nontoxic doses and enhance an anti-hapten humoral
response that consists of major IgG subclasses, especially
IgG2a. They are equally capable of provoking anti-tumor
cytotoxic T cell response. Moreover, unlike conventional
adjuvants, phytol-derived PHIS-01 shows little toxicity or
nephritogenic pathology resulting from induction of a
cross-reactive anti-DNA antibody response. In our ongo-
ing study, we have also noted that the phytol and PHIS-01
are superior adjuvants in eliciting anti-bacterial immune
responses [24].
Methods
Immunological Studies
We studied the effects of commercial and experimental
adjuvants on different immune parameters such as anti-
gen-specific humoral responses, antibody isotypes, cell-
mediated anti-tumor immunity, and autoimmune reactiv-
ity in BALB/c, C57Bl/6, and autoimmune-prone NZB
mice. Gender-matched, 8–12 weeks old BALB/c and
C57Bl/6 mice were bred in the animal facility of Indiana
State University. To determine autoimmune parameters,
six-week-old NZB/W F1 and NZB female mice (Harlan
Sprague Dawley, Indianapolis, IN) were used. All animal
experiments were performed according to guidelines of
laboratory animal care (NIH publication 85-23), using
specific protocols approved by the Animal Care and Use
Committee (ACUC) of Indiana State University.
The commercial adjuvants used in this study consisted of
CFA, IFA, Titermax, and RAS (Sigma Chemical Co., St.
Louis, IL); phytol (Pfaltz and Bauer Inc., Waterbury, CT);
and Alhydrogel (Accurate Chemical and Scientific Corp.,
Westbury, NY). Pristane (Sigma, St. Louis, IL) was also
used for comparative assessment of plasmacytomagenic
potential. Our experimental adjuvant consisted of phytol
and a phytol derivative, PHIS-01 (patent pending). The
latter was obtained by chemical reduction of phytol into
phytanol following a published procedure [25].
Anti-tumor vaccine efficacy
A B-cell lymphoma 2C3 was used in this study. We have
extensively used this tumor model in previous studies [26-
28]. This tumor, which secretes anti-phthalate 2C3-Ig, was
generated from fusion of phthalate-KLH-primed BALB/c
splenocytes with a non-secreting myeloma, X63-Ag8.653.
Two other anti-phthalate hybridomas, designated as 1H5
and 3B4, which show high specificity for phthalate and
DNA, were also previously described [27].Journal of Immune Based Therapies and Vaccines 2006, 4:6 http://www.jibtherapies.com/content/4/1/6
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We also studied another tumor model, Ia-negative EL4
thymoma (H-2b) and EL4 cells transfected with ovalbu-
min (OVA)-cDNA gene (E.G7-OVA) obtained from Amer-
ican Type Culture collection (ATCC, Rockville, MD).
Using this tumor model, we assessed OVA-antigen-spe-
cific CTL in C57BL/6 mice.
Adjuvants on humoral response
Adjuvant effect on antibody response was studied in
BALB/c (five or more in a group) which were injected
intraperitoneally (IP) with phthalate-KLH conjugates (in
BALB/c) emulsified in experimental or conventional adju-
vants in a total volume of 400 μL (100 μg of each antigen).
Control groups of mice were immunized with PBS only.
Subsequent immunizations also contained adjuvants and
were given at 10-day intervals. The mice were bled
through retro-orbital veins five days after each immuniza-
tion.
For assessment of antigen-specific cytotoxic effector activ-
ity, we used ovalbumin (OVA in 5 or more C57Bl/6 mice)
also emulsified with adjuvants as above. We also assessed
the efficacy of adjuvants in generating tumor-specific cyto-
lytic response against the 2C3 tumor model in BALB/c
mice. The latter group was repeatedly immunized with
killed 2C3 tumor cells before spleens were dissected out
for isolation and assessment of cytotoxic effector cells.
Enzyme-linked immunosorbent assays (ELISA)
Indirect ELISA was performed to assess and correlate dif-
ferent humoral responses [26]. Serum antibodies were
tested for their specificities to phthalate on polyvinyl 96-
well flat bottom plates (Falcon) coated with either phtha-
late (as a conjugate of BSA) or calf thymus DNA. After the
plates were blocked with 1% BSA/PBS O.N. at 4°C, vari-
ous dilutions of sera (10–10000) were added to each well,
and the plates were incubated for 1 hr at 37°C. The wells
were washed with phosphate-buffered saline-containing
0.05% triton X, and rabbit anti-mouse Ig-HRP (50 μL) (at
1:3000 dilution) was added. Plates were incubated for 1
hr and washed again. Bound rabbit anti-mouse Ig-HRP
was detected by addition of o-phenylene diamine (OPD)
and hydrogen peroxide. The reaction was stopped with 50
uL of 10% H2SO4, and the color intensity was read at 490
nm.
Generation of cytolytic effector cells
C57BL/6 mice were given three injections with OVA emul-
sified in test adjuvants. Spleen cells were obtained from
C57Bl/6 mice on day 7 after the 3rd immunization and
prepared for 51Cr-release cytotoxicity assay [28]. For lym-
phoma, BALB/c mice were injected with each adjuvant 5
days before administration of live 2C3 tumor (5 × 106
cells/mouse). Splenocytes were harvested on day 8 and
stimulated with killed 2C3 cells before 51Cr-release cyto-
toxicity assay.
Splenocytes were seeded into 6-well tissue culture plates
at 6 × 106 cells/well in 2 ml RPMI/10% FBS, and then
stimulated in vitro with killed E.G7-Ova cells or 2C3 cells
(1.2 × 106 cells/well) for 5 days in the presence of 10%
CO2 at 37°C to generate cytotoxic effector cells.
Cytotoxicity assay
As previously described, the target cells were labeled at
37°C with 150 μCi of sodium 51Cr for 1 hr, washed three
times in PBS, and then resuspended in RPMI/10% FBS
[28]. The labeled target cells were then dispensed at 5 ×
103  cells/well into 96-well plates. Effector splenocytes
were added at various E:T ratios with appropriate target
cells seeded in 96-well plates. The total volume of the
reaction was 200 μL/well. The plates were incubated at
37°C for 6 h, after which they were centrifuged, and 30 μL
of supernatant removed from each well was added to 96-
well lumina plates to assess 51Cr release in a Top Count-
NXT plate reader (Packard Instruments, Meriden, CT,
USA). The percent specific lysis was determined by the for-
mula: percent specific lysis = (sample release - spontane-
ous release/maximum release - spontaneous release) ×
100. Spontaneous release never exceeded 18% of the max-
imum release. All cytolytic analyses described in this study
were performed in triplicate and repeated at least three
times in separate experiments. Specifically, the measure-
ment of OVA-specific cytotoxic effector cell activity was
performed using E.G7-OVA and EL4 cells as targets in
C57Bl/6 mice, the latter serving as the negative control
against OVA-specific effectors. For 2C3-lymphoma-spe-
cific cytotoxicity studies, 2C3 and a mastocytoma P815
were used as targets. P815 cells served as the negative con-
trol.
Statistical analysis
The paired Student's t-test (Sigma Plot software) was used
to determine statistical significance. Levels of p < 0.05
were considered statistically significant. Data are
expressed as mean ± S.E.M.
Results
Generation of anti-phthalate antibody response in BALB/c 
mice
Groups of 5 mice were injected with 100 μg of phthalate-
KLH admixed with an adjuvant as described previously
[27-29]. The commercially available adjuvants CFA, IFA,
alhydrogel, pristane, TiterMax Gold, and Ribi Adjuvant
System (RAS) were used in the preparation of immunogen
according to the manufacturers' protocols. For phytol and
PHIS-01, we adopted the protocol recommended for IFA/
CFA. In order to compare adjuvanticity, mice were given
identical doses of the antigen in each experiment. The effi-Journal of Immune Based Therapies and Vaccines 2006, 4:6 http://www.jibtherapies.com/content/4/1/6
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cacy of each adjuvant was evaluated by measuring serum
antibody levels 5 days after each immunization. The
results show that to a varying degree, all adjuvants tested
augmented both 1° and 2° antibody responses to the
phthalate conjugate (Fig 1A and 1B). There was little
change in the magnitude of antibody responses in all
groups of mice immunized during follow-up over a
period of 2 months (data not shown). Interestingly, the
2° anti-phthalate antibody response was boosted as effec-
tively by PHIS-01 and phytol adjuvants as by CFA/IFA
combination or RAS. In contrast, TiterMax and Alum were
ineffective (Fig. 1B).
Effects of PHIS-01 and other adjuvants on induction of IgG 
subclasses
The effectiveness of a vaccine formulation depends to a
large extent on the type of antibody subclasses induced,
and adjuvants are known to play significant roles in vac-
cine efficacy. In this study, we determined by isotyping the
effects of various adjuvants on induction of different IgG
subclasses. Significant differences were indeed observed
with the use of different adjuvants (Fig. 2). It is evident
that all adjuvants tested favored IgG1 subclass; however,
only PHIS-01 was also effective in induction of significant
levels of IgG2a and IgG3 anti-phthalate antibodies sug-
gesting a shift toward the Th1 type immune response. Evi-
dently, the ratio of IgG1 to IgG2a Abs was <1 only in mice
immunized with phthalate emulsified with PHIS-01.
Induction of anti-tumor effector T cells
Since induction of cytolytic effector cells is pivotal in
ensuring the success of tumor vaccines, we investigated
relative efficacy of phytols and known adjuvants in their
ability to augment antigen-specific CTL activity in C57BL/
6 and BALB/c mice using two different tumor models,
E.G7-OVA and 2C3 respectively. Splenocytes from C57Bl/
6 mice immunized with OVA emulsified in various adju-
vants were stimulated in vitro with killed E.G7-OVA
tumor cells and then evaluated for cytolytic activity
against E.G7-OVA and untransfected EL4 cells. The results
in Fig. 3A clearly show that phytols, unlike Alum, in vac-
cine formulation could elicit tumor-specific cell-mediated
effector activity, albeit to a lesser degree than CFA/IFA.
This effector-population was antigen-specific, as untrans-
fected EL4 cells were not lysed (data not shown).
We previously reported induction of idiotype-specific
cytotoxic T-lymphocytes (CTL) in BALB/c mice following
prophylactic immunization with killed 2C3 tumors or
during early stages of 2C3 tumor growth in vivo [30].
Using this model, we investigated whether this tumor-spe-
cific CTL response is augmented by injection of adjuvants
and live 2C3 cells. As shown in Fig 3B, splenocytes of mice
injected with phytol and particularly, PHIS-01 exhibited
significant CTL response against 2C3 tumor target cells.
These splenocytes had no cytotoxic activity against anti-
gen-negative control tumors P815 (data not shown). In
contrast, the commercial adjuvants CFA/IFA or Alum were
ineffective against 2C3 B-lymphoma (Fig. 3B).
Evaluation of toxicity and safety of phytol adjuvants
Adjuvants in general enhance interactions between innate
and acquired immunity by mobilizing and activating the
former, possibly by promoting danger signals [31,32]. In
order to assess relative toxicity or inflammatory effects of
the phytol and PHIS-01, we administered them in various
concentrations (40–100 μg) via intraperitoneal routes to
mice weighing about 20 g. Mice were weighed prior to
treatment and at regular intervals thereafter throughout a
period of one week, and then sacrificed to examine the
major organs, such as liver and spleen. As shown in Table
1, the LD50 of PHIS-01 was much greater than 8 mg/kg
bodyweight in mice, whereas all mice injected with the
same dose of phytol were dead within 4 days. The differ-
ence between the body weight gain/loss in the test and
control animals was less than 10% among groups of mice
injected with <40 μg of phytol or PHIS-01. Furthermore,
phytol induced splenomegaly comparable to that seen in
mice treated with CFA (Fig 4A and 4B), but there was no
sign of splenomegaly with 40–80 μg of PHIS-01 (Fig. 4B).
Average spleen weights and cell numbers for each group
of mice were reported in Table 2.
Induction of lupus-autoantibodies by adjuvants
Although adjuvants such as CFA/IFA, or even pristane,
effectively augment the immunogenic potentials of weak
vaccines, they also induce lupus-type autoantibodies in
most normal strains of mice [22,23]. It is not known
whether this ability to induce lupus is unique to mineral
oil adjuvants. To determine whether phytol products also
induce lupus-type autoantibodies, we tested sera of
phthalate-immunized BALB/c, NZB, and lupus-prone
NZB/W F1 mice for cross-reactive anti-DNA responses. We
previously reported such responses using adjuvants such
as CFA and IFA [27-29]. As shown in Fig. 5, BALB/c mice
immunized with phthalate in pristane induced high levels
of anti-DNA autoantibodies after the 3rd immunization.
Similar autoantibodies were also produced, albeit at lower
levels, by mice immunized with CFA/IFA and RAS. How-
ever, both phytol and PHIS-01 had no significant effects
on the production of anti-DNA Abs.
No signs of glomerulonephritis in phytol-treated mice
Further evaluation of safety and toxicity was assessed by
histopathology of the kidneys from mice treated with phy-
tol, PHIS-01 and IFA/CFA. Blood urea nitrogen (BUN)
and proteinuria of autoimmune-prone NZB/W F1 mice
immunized with phthalate-KLH in phytols or IFA/CFA
were tested for by using Azostix (Bayer, Elkart, IN) and
Multistix (Bayer, Elkart, IN) respectively. As described pre-Journal of Immune Based Therapies and Vaccines 2006, 4:6 http://www.jibtherapies.com/content/4/1/6
Page 5 of 11
(page number not for citation purposes)
Anti-phthalate antibody response in BALB/c mice following vaccination with ortho-phthalate-KLH conjugate emulsified in vari- ous adjuvants Figure 1
Anti-phthalate antibody response in BALB/c mice following vaccination with ortho-phthalate-KLH conjugate emulsified in vari-
ous adjuvants. Serum samples were collected on day 5 after 1° (Fig. 1A) and 2° (Fig. 1B) immunizations and assessed by ELISA, 
as described. The results represent mean ± SD (n = 5 mice per group in two separate experiments).
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viously [27], mice immunized with phthalate in IFA/CFA
reveal almost 3–4-fold higher BUN and urinary protein
level indicating severe nephritis than those of control
mice; however, no such kidney pathology was observed
using phytol or PHIS-01 as adjuvants (data not shown).
Ascites production in BALB/c mice using pristane and 
phytols
Mineral oils, pristane in particular, have been shown to
promote ascites formation and induction of plasmacy-
toma in BALB/c mice [33-36]. To ascertain whether phytol
and PHIS-01 exert similar effects, BALB/c mice were
primed intraperitoneally with pristane, phytol, or PHIS-
01. In contrast to pristane, phytol and PHIS-01 exhibited
no plasmacytomagenic properties in preliminary studies.
Nonetheless, as shown in Table 3, phytol was found to be
comparable to pristane as a primer for propagation of
hybridoma lines in vivo.
Discussion
The importance of safe and effective adjuvants in vaccine
research cannot be overstated, and there is a growing
need, not only for new vaccines but for new adjuvants as
well. Most newly developed vaccines are based on selected
target antigens consisting of single molecules or fragments
derived from infectious microorganisms, or tumor cells.
They are administered in the form of purified proteins,
synthetic peptides, or vectored DNA. Such vaccines are
usually poorly immunogenic and costly and/or difficult to
produce. Moreover, many widely used vaccines can lose
their effectiveness due to repeated use and for other bio-
logical reasons. Adjuvants can override such immunolog-
ical inadequacy and help mount effective immune
responses. Although in the past most vaccines have been
designed to stimulate antibody responses, vaccines cur-
rently in development are increasingly designed to elicit
cellular immune responses involving Th1 cells, and CTLs.
Such responses are required to control chronic infectious
diseases associated with viruses and intracellular patho-
gens, and also for the development of therapeutic vaccines
against cancer.
In this study, we determined the adjuvanticities of chloro-
phyll-derived phytol and its chemically reduced deriva-
tive, PHIS-01, relative to those of commonly used
commercial adjuvants. In the first study, mice were immu-
nized with a hapten, phthalate, conjugated to KLH in one
of the several adjuvants: phytol, PHIS-01, CFA, IFA, pris-
tane, TiterMax, Ribi adjuvant system, and Alhydrogel or
alum. Effectiveness was measured in terms of quantity,
specificity, duration, and isotype of Abs generated. In
another experiment, phytol, PHIS-01, CFA, and IFA were
used to study induction of cell-mediated immunity, espe-
cially tumor specific CTL response to either OVA-trans-
fected EL4 thymoma or 2C3 lymphoma in C57Bl/6 and
BALB/c mice respectively. In addition, this study also
addressed the issue of safety relative to efficacy of phytol-
based adjuvants. Safety evaluation has been performed
from the perspectives of toxicity, and the ability to induce
adverse autoimmune reaction and plasmacytoma forma-
tion.
In this report, phthalate-protein conjugate was selected as
the immunogen because of our previous finding that the
anti-phthalate antibody response induced with IFA as the
adjuvant elicits cross-reactive anti-DNA antibodies engen-
dering lupus-like syndromes with kidney pathology [27-
29]. We also reported that this adverse cross-reactivity is
exacerbated by many commonly used adjuvants. Assess-
ment of anti-phthalate and cross-reactive anti-DNA anti-
body responses in the presence of various adjuvants is
thus a novel approach for evaluating the safety and effec-
tiveness of adjuvants. In this investigation, we observed
that phytol and PHIS-01 effectively enhance the immuno-
genicity of phthalate-conjugate without inducing anti-
DNA antibodies. The mechanism underlying the suppres-
sion of this autoimmune reaction due to phthalates
remains unclear.
Further evidence for the efficacy of phytol, and especially
PHIS-01, as adjuvants, can be gleaned from the quality
and levels of IgG responses elicited. PHIS-01-treated mice
exhibited excellent anti-phthalate IgG2a response. This
isotype is most desirable in therapeutic applications,
because of its ability to activate complement cascades, and
Assessment of classes and subclasses of phthalate-specific  serum IgG antibodies induced in response to immunizations  with ortho-phthalate-KLH conjugates in various adjuvants Figure 2
Assessment of classes and subclasses of phthalate-specific 
serum IgG antibodies induced in response to immunizations 
with ortho-phthalate-KLH conjugates in various adjuvants. 
The above serum samples were subjected to ELISA using 
commercial isotyping kits as described in Methods.
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Induction of tumor specific-cytotoxic effector responses Figure 3
Induction of tumor specific-cytotoxic effector responses. Spleen cells were obtained from C57BL/6 mice on day 7 after 
3rd immunization with OVA in test adjuvants. BALB/c mice were given injection of test adjuvants 5 days before challenge with 
the B-cell lymphoma, 2C3 and sacrificed on day 8. Splenocytes harvested were stimulated with either killed E.G7-OVA or 2C3 
cells in vitro for 5 days. Effector cells harvested on the fifth day were assayed in a 51Cr-release cytotoxicity assay as described 
under Methods. The results shown represent the mean of triplicates ± SD from two separate experiments (n = 3 mice per 
group/experiment). A. OVA-specific CTL response from C57BL/6 mice. B. Tumor-specific CTL response from BALB/c mice
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Ab-dependent cellular cytotoxicity which in turn ensures
better protection against tumor or parasites. Moreover,
induction of IgG2a is an indirect measure of the relative
contributions of Th1 and Th2 cells. It remains to be deter-
mined whether this isotype switch reflects changes in
cytokine milieu brought about by the phytol-based adju-
vants.
In many instances, specific antigen-adjuvant combina-
tions have been shown to promote antigen-specific pro-
duction of Th1 type cytokines of (IFN-γ, IL-2) and
cytotoxic T-cell responses [36-38]. However, there is as yet
no specific combination that ensures sustained activity in
terms of magnitude and duration of cell-mediated
immune response. Our studies reveal that mice pre-
Demonstration of splenomegaly in mice treated with different adjuvants Figure 4
Demonstration of splenomegaly in mice treated with different adjuvants. Groups of 3–4 BALB/c mice were intra-
peritoneally injected with each adjuvant, and after 5 days their spleens were dissected out for observation. A representative 
result is shown below: (A) Effects ofvarious adjuvants on spleen size: 1. Spleens from mice injected with PBS. 2. Spleen from 
mice injected with Pristane. 3. Spleen from mice injected with IFA. 4. Spleen from mice injected with CFA. 5. Spleen from mice 
injected with Phytol. (B) Effects of different doses of phytols on spleens: 1. Spleen from mice injected with 100 μl of PBS. 2. 
Spleen from mice injected with 80 μg of Phytol. 3. Spleen from mice injected with 40 μg of Phytol. 4. Spleen from mice injected 
with 80 μg of PHIS-01. 5. Spleen from mice injected with 40 μg of PHIS-01
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treated with phytol, and especially PHIS-01, mount an
effective CTL response recognizing lymphoma-associated
Ig idiotype. Neither CFA/IFA nor alhydorgel appear to
induce a similar response. However, when C57Bl/5 mice
are immunized with soluble OVA and phytol or PHIS-01,
cytotoxic effector activity of their spleen cells exhibit sig-
nificant enhancement, although not as much as CFA/IFA.
In conclusion, phytol and PHIS-01 adjuvants appear to be
more versatile as immunostimulants on the basis of their
ability to promote effective humoral and cell-mediated
immune responses. This is further evident in another
study in which we assessed their adjuvanticity in engen-
dering effective antibacterial responses [24]. In terms of
toxicity, PHIS-01 induces little, if any, splenomegaly,
implying no significant pro-inflammatory effects, and
therefore is more useful than phytol. Further, only small
amounts of phytol and PHIS-01 are required to stimulate
immune responses. None of these two compounds stim-
ulates reaginic immune responses, nor induces autoim-
mune lupus-like syndromes. Most importantly, phytol
and PHIS-01 support hybridoma propagation in vivo
without inducing formation of granulomatous tissue on
peritoneal surfaces, which is a problem with pristane.
Also, unlike pristane, these novel adjuvants have no effect
on plasmacytoma development in BALB/c. In future stud-
ies, we plan to determine whether or not the differences in
efficacy are due to a distinct cytokine milieu generated by
these compounds
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